Cincera Therapeutics is a privately held biotechnology company based in Melbourne, Australia. The company is focused on the discovery and development of new drugs aiming to treat difficult-to-treat inflammatory and fibrotic conditions associated with obesity/metabolic diseases, with potential applications in many other disease areas including cancer. The company will initially focus on treatments for the emerging epidemic of a liver disease termed ‘NASH’ (non-alcoholic steatohepatitis). The Cincera team has developed novel drug like lead compounds that specifically inhibit a key enzymatic target in a lipid metabolism pathway. The novel and differentiated approach of Cincera is derived from the innovative research of its academic co-founders: medicinal chemist and entrepreneur Associate Professor Bernard Flynn, from the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University (Monash) in Melbourne, and lipid biologist Professor Stuart Pitson, from the Centre for Cancer Biology (CCB) at the University of South Australia (UniSA) in Adelaide. The company is funded by the Medical Research Commercialisation Fund (MRCF), which is managed by the life science specialist venture capital management firm – Brandon Capital Partners (BCP).
Cincera Therapeutics is a privately held biotechnology company based in Melbourne, Australia. The company is focused on the discovery and development of new drugs aiming to treat difficult-to-treat inflammatory and fibrotic conditions associated with obesity/metabolic diseases, with potential applications in many other disease areas including cancer. The company will initially focus on treatments for the emerging epidemic of a liver disease termed ‘NASH’ (non-alcoholic steatohepatitis). The Cincera team has developed novel drug like lead compounds that specifically inhibit a key enzymatic target in a lipid metabolism pathway. The novel and differentiated approach of Cincera is derived from the innovative research of its academic co-founders: medicinal chemist and entrepreneur Associate Professor Bernard Flynn, from the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University (Monash) in Melbourne, and lipid biologist Professor Stuart Pitson, from the Centre for Cancer Biology (CCB) at the University of South Australia (UniSA) in Adelaide. The company is funded by the Medical Research Commercialisation Fund (MRCF), which is managed by the life science specialist venture capital management firm – Brandon Capital Partners (BCP).
Company Information
- Industry
- Biotechnology
- Company Type
- Privately Held
- Founded
- 2018
- Employee Range
- 1-10
- Revenue Range
- Not available
Location
- Address
- 31 Queen Street VIC Melbourne
- City
- Region
- Postal Code
- 3000
- Country
- Australia